A thesis at Karbala University College of Medicine discussed the classification of diffuse gliomas into different subgroups on the basis of molecular markers, which divide patients into better predictive groups than tissue classification. Therefore, classification of diffuse gliomas, treatment and prognosis are affected by mutations that can be identified through genetic studies and immunohistochemical parameters. Being a powerful scientific method in contrast to high-cost DNA sequencing techniques, the thesis titled ((Use of IDH1, ATRX, P53 Immunoassay Parameters as Alternatives for Molecular Genetic Classification of Brain Glial Tumors with Prediction of Clinical End of Different Grades of These Tumors)) by Heba Ahmed Hussein Salman Al-Mayali is one of the students of the Iraqi Board of Medical Specialties in the pathology branch. The thesis also aimed at the importance of chemical examination in the clinical prognosis and classification of gliomas of the second, third and fourth degree, which were divided in the study. p53) is of importance in the classification of gliomas and in reaching a clinical outcome for these tumors The study discussed 51 patients diagnosed with grade II to IV diffuse gliomas, using formalin-fixed paraffin-embedded tissue blocks from 51 tumor cases of different grades and types. Histological sections for evaluation using anti-IDH1, ATRX, p53 antagonists for immunostaining procedure, which were crossed in the form of positive and negative status, determined the association between clinical indicators and pathological factors and patient survival.
